Major Companies in the Taiwan Ankylosing Spondylitis Market | Key Players & Insights 2026

Taiwan Ankylosing Spondylitis Market Overview

According to 6Wresearch, the market for ankylosing spondylitis in Taiwan is currently undergoing tremendous growth, due to the rising occurrence of the condition and the growing need for effective treatment solutions. Ankylosing Spondylitis is a chronic inflammatory disease that affects the spine and other joints, hence the need for proper management within the island's aging and health-conscious population.

Today, the market is driven by the growing trend of using biologics and biosimilars, which offer patients effective solutions on how to manage the condition effectively. In addition, various initiatives have been put in place by the government, to ensure improved healthcare services and expanded universal health coverage, which further boosts the market growth.

Competitive Landscape

The competitive landscape of the Taiwan ankylosing spondylitis industry encompasses several global manufacturers, alongside local biotech innovators. The market position of the dominant companies is sustained with continued investment in R&D, which helps in the development of innovative drugs like IL-17 and JAK inhibitors, that caters to the growing need for effective ankylosing spondylitis drugs.

Below is a list of leading players operating in the Taiwan Ankylosing Spondylitis Market:

1. AbbVie Taiwan

AbbVie is a dominant leader with its TNF inhibitor, that remains a primary treatment option for patients with active ankylosing spondylitis.

2. Novartis Taiwan

Novartis provides essential IL-17A inhibitors, which have gained significant traction for patients who are unresponsive to traditional therapies.

3. Pfizer Taiwan

Pfizer is a major player in the biologics space, offering established TNF-alpha blockers and expanding its portfolio with JAK inhibitors.

4. Johnson & Johnson Taiwan (Janssen)

Janssen is a key player in providing monoclonal antibodies and long-acting biologics that target specific inflammatory pathways in spondylarthritis.

5. Amgen Taiwan

Amgen focuses on specialized biological therapies and has a growing presence in the biosimilar market, providing high-quality treatment alternatives.

6. Eli Lilly Taiwan

Eli Lilly provides critical IL-17 inhibitors used extensively for patients suffering from radiographic axial spondylarthritis and psoriatic arthritis.

7. UCB Taiwan

UCB is a leading player providing PEGylated TNF inhibitors, which offer a unique therapeutic option, especially for women of childbearing age.

8. Mycenax Biotech Inc.

Mycenax is a prominent domestic biotech firm engaged in the development of biosimilars, aiming to lower the cost of advanced biological treatments.

9. EirGenix Inc.

EirGenix is an emerging player focused on the contract development and manufacturing of high-quality biologics and biosimilars for autoimmune diseases.

10. Bristol-Myers Squibb (BMS) Taiwan

BMS is a prominent player offering selective T-cell costimulation modulators and researching new pathways for managing systemic inflammatory responses.